- Home
- LUNG
LUNG
Pulmonx Corporation
as 03-28-2025 4:00pm EST
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 299.3M | IPO Year: | 2020 |
| Target Price: | $12.64 | AVG Volume (30 days): | 253.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.46 - $10.01 | Next Earning Date: | 04-30-2025 |
| Revenue: | $83,789,000 | Revenue Growth: | 22.01% |
| Revenue Growth (this year): | 17.96% | Revenue Growth (next year): | 18.35% |
Stock Insider Trading Activity of Pulmonx Corporation (LUNG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Joshi Mehul | LUNG | Chief Financial Officer & PAO | Mar 3 '25 | Sell | $7.12 | 14,384 | $102,414.08 | 113,986 | |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Mar 3 '25 | Sell | $7.13 | 5,779 | $41,193.02 | 290,537 | |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Mar 3 '25 | Sell | $7.31 | 22,355 | $170,920.96 | 191,515 | |
| Williamson Steven S. | LUNG | PRESIDENT AND CEO | Mar 3 '25 | Sell | $7.14 | 27,689 | $197,699.46 | 194,342 | |
| French Glendon E. III | LUNG | Director | Feb 20 '25 | Sell | $8.45 | 55,453 | $459,085.96 | 1,011,974 | |
| French Glendon E. III | LUNG | Director | Jan 16 '25 | Sell | $6.52 | 4,547 | $29,625.28 | 1,011,974 |
Latest Pulmonx Corporation News
LUNG Breaking Stock News: Dive into LUNG Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Pulmonx Full Year 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
a month ago
Q4 2024 Pulmonx Corp Earnings Call
GuruFocus.com
a month ago
Pulmonx Corp (LUNG) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Financial ...
Zacks
a month ago
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
a month ago
What To Expect From Pulmonx Corp (LUNG) Q4 2024 Earnings
Zacks
a month ago
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last?
GlobeNewswire
a month ago
Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day
Compare LUNG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.